

CONTACT | Media:

+31.20.550.4488 (Amsterdam), +32.2.509.1392 (Brussels)

+351.217.900.029 (Lisbon), +44.20.7379.2789 (London)

+1.212.656.2411 (New York), +33.1.49.27.11.33 (Paris)

CONTACT | Investor Relations: +1.212.656.5700 (New York) +33.1.49.27.58.60 (Paris)

NYSE Euronext Announces Trading Volumes for January 2012

Global Derivatives ADV Down 17% Year-over-Year European Cash ADV Down 15%; U.S. Cash ADV Down 24%

February 8, 2012 – NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for January 2012¹. Trading volumes declined year-over-year across most venues, but generally rebounded from seasonally slower December 2011. Global derivatives average daily volume ("ADV") of 7.5 million contracts in January 2012 decreased 17.3% versus the prior year, with European Derivatives declining 31.3% and U.S. equity options decreasing 4.1%. European cash trading ADV decreased 14.6% and U.S. cash trading ADV decreased 23.5% from January 2011 levels.

Highlights

- NYSE Euronext global derivatives ADV in January 2012 of 7.5 million contracts decreased 17.3% compared to January 2011, but increased 0.3% from December 2011 levels.
- NYSE Euronext European derivatives products ADV in January 2012 of 3.2 million contracts decreased 31.3% compared to January 2011 and decreased 6.3% from December 2011 levels. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV decreased 28.3% compared to January 2011, but increased 21.6% from December 2011.
- NYSE Euronext U.S. equity options ADV of 4.2 million contracts in January 2012 decreased 4.1% compared to January 2011 levels, but increased 6.0% from December 2011. NYSE Euronext's U.S. options exchanges accounted for 26.6% of total U.S. consolidated equity options trading in January 2012, up from 24.5% in January 2011, but down from 27.7% in December 2011.
- NYSE Liffe U.S. ADV of approximately 94,900 contracts increased from 13,500 contracts in January 2011 and increased from 89,600 contracts in December 2011.
- NYSE Euronext European cash products ADV of 1.5 million transactions in January 2012 decreased 14.6% compared to January 2011, but increased 12.9% from December 2011 levels.
- NYSE Euronext U.S. cash products handled ADV of 1.8 billion shares in January 2012 decreased 23.5% compared to January 2011, but increased 1.1% compared to December 2011. NYSE Euronext's Tape A matched market share in January 2012 was 30.3%, down from 33.9% in January 2011 and down from 33.4% in December 2011. Trade Reporting Facility ("TRF") market share in Tape A securities, a measure of off-exchange trading, increased to 34.1% of consolidated U.S. cash equity trading in Tape A securities in

All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

- January 2012, the highest level since January 2010, and up from 31.1% in December 2011 and 33.1% in January 2011.
- There were a total of 22 trading days in Europe and 20 trading days in the U.S. in January 2012 compared to 21 trading days in Europe and 20 trading days in the U.S. in January 2011.

Derivatives Trading

European Derivatives

- NYSE Euronext European derivatives products ADV in January 2012 was 3.2 million futures and options contracts, a decrease of 31.3% from January 2011, but an increase of 0.3% from December 2011.
- The 3.2 million in European derivatives futures and options contracts ADV in January 2012 consisted of 2.7 million contracts executed through our full-service LIFFE CONNECT trading platform and 0.5 million contracts, or 16.9%, executed through Bclear, NYSE Liffe's trade administration and clearing service for OTC products. Excluding Bclear, European derivatives products ADV decreased 28.3% compared to January 2011, but increased 21.6% from December 2011.
- Total fixed income products ADV of 1.8 million contracts in January 2012 decreased 29.7% from January 2011, but increased 36.2% from December 2011.
- Total equity products (including Bclear) ADV of 1.3 million contracts in January 2012 decreased 34.5% compared to January 2011 and decreased 9.0% from December 2011. The 1.3 million contracts in equity products ADV consisted of 0.9 million contracts in individual equity products ADV and 0.4 million contracts in equity index products ADV. The 0.9 million contracts in individual equity products ADV consisted of 0.4 million in futures contracts, which represented a 46.5% decrease compared to January 2011 and 0.5 million in options contracts, which represented a 29.9% decrease compared to January 2011. The average net rate per contract for individual equity futures contracts is significantly lower than other European derivatives products.
- Total commodities products ADV of 75,000 contracts in January 2012 increased 1.0% compared to January 2011 and increased 10.3% compared to December 2011.

U.S. Derivatives

- NYSE Euronext U.S. equity options ADV of 4.2 million contracts in January 2012 decreased 4.1% compared to January 2011, but increased 6.0% compared to December 2011.
- Total U.S. consolidated equity options ADV decreased 11.7% to 15.7 million contracts in January 2012 compared to January 2011, but increased 10.2% compared to December 2011.
- NYSE Euronext's U.S. options exchanges accounted for 26.6% of the total U.S. consolidated equity options trading in January 2012, up from 24.5% in January 2011, but down from 27.7% in December 2011.
- NYSE Liffe U.S. ADV of approximately 94,900 contracts increased from 13,500 contracts in January 2011 and increased from 89,600 contracts in December 2011.

Cash Trading

European Cash

• NYSE Euronext European cash products ADV of 1.5 million transactions in January 2012 decreased 14.6% compared to January 2011, but increased 12.9% compared to December 2011.

U.S. Cash

- NYSE Euronext U.S. cash products handled ADV in January 2012 decreased 23.5% to 1.8 billion shares compared to January 2011, but increased 1.1% from December 2011.
- NYSE Euronext's Tape A matched market share in January 2012 was 30.3%, down from 33.9% in January 2011 and down from 33.4% in December 2011. TRF market share in Tape A securities, a measure of off-exchange trading, increased to 34.1% of consolidated U.S. cash equity trading in Tape A securities in January 2012, the highest level since January 2010, and up from 31.1% in December 2011 and 33.1% in January 2011.

Exchange Traded Funds

• NYSE Euronext U.S. matched exchange-traded funds ADV (included in volumes for Tape B and Tape C) of 228 million shares in January 2012 decreased 15.6% compared to January 2011 and decreased 8.1% compared to December 2011.

Please click here for the Monthly Transaction Activity Data Table.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: http://www.nyx.com.

Disclaimer and Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext's results to differ materially from current expectations include, but are not limited to: NYSE Euronext's ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext's reference document for 2010 ("document de référence") filed with the French Autorité des Marchés Financiers (Filed on April 19, 2011 under No. D.11-0333), 2010 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.

NYSE Euronext Monthly Volume Summary

	Average Daily Volume			Total Volume			Average Daily Volume		Total Volume	
		-						% Chg vs.		% Chg vs.
(Unaudited; contracts in thousands)	Jan-12	Jan-11	% Chg	Jan-12	Jan-11	% Chg	YTD 2011	YTD 2010	YTD 2011	YTD 2010
Number of Trading Days - European Markets Number of Trading Days - U.S. Markets	22 20	21 20		22 20	21 20		22 20		22 20	
European Derivatives Products	3,222	4,688	-31.3%	70,891	98,441	-28.0%	3,222	-31.3%	70,891	-28.0%
of which Bclear	546	954	-42.8%	12,014	20,044	-40.1%	546	-42.8%	12,014	-40.1%
Total Fixed Income Products	1,842	2,622	-29.7%	40,529	55,060	-26.4%	1,842	-29.7%	40,529	-26.4%
Short Term Interest Rate Products Medium and Long Term Interest Rate Products ¹	1,723 119	2,515 106	-31.5% 12.1%	37,904 2,625	52,825 2,234	-28.2% 17.5%	1,723 119	-31.5% 12.1%	37,904 2,625	-28.2% 17.5%
Total Equity Products ²	1,305	1,991	-34.5%	28,711	41,821	-31.3%	1,305	-34.5%	28,711	-31.3%
Individual Equity Products	906	1,470	-38.3%	19,936	30,863	-35.4%	906	-38.3%	19,936	-35.4%
Futures	402	750	-46.5%	8,837	15,753	-43.9%	402	-46.5%	8,837	-43.9%
Options Equity Index Products	504 399	720 522	-29.9% -23.6%	11,099 8,775	15,110 10,958	-26.5% -19.9%	504 399	-29.9% -23.6%	11,099 8,775	-26.5% -19.9%
of which Bclear	546	954	-42.8%	12,014	20,044	-40.1%	546	-42.8%	12,014	-40.1%
Individual Equity Products	486	887	-45.1%	10,701	18,617	-42.5%	486	-45.1%	10,701	-42.5%
Futures	402	750	-46.4%	8,837	15,747	-43.9%	402	-46.4%	8,837	-43.9%
Options Equity Index Products	85 60	137 68	-38.0% -12.2%	1,865 1,312	2,870 1,427	-35.0% -8.0%	85 60	-38.0% -12.2%	1,865 1,312	-35.0% -8.0%
Commodity Products	75	74	1.0%	1,651	1,560	5.8%	75	1.0%	1,651	5.8%
U.S. Derivatives Products										
Equity Options ³										
NYSE Euronext Options Contracts	4,171	4,350	-4.1%	83,425	86,998	-4.1%	4,171	-4.1%	83,425	-4.1%
Total Consolidated Options Contracts	15,668	17,740	-11.7%	313,363	354,796	-11.7%	15,668	-11.7%	313,363	-11.7%
NYSE Group Share of Total NYSE Liffe U.S.	26.6%	24.5%		26.6%	24.5%		26.6%	2.1%	26.6%	2.1%
Futures and Futures Options Volume*	94.9	13.5	603.1%	1,993	283	603.1%	94.9	603.1%	1,992.7	603.1%
European Cash Products (trades in thousands)	1,510	1,768	-14.6%	33,222	37,138	-10.5%	1,510	-14.6%	33,222	-10.5%
Equities	1,455	1,699	-14.3%	32,020	35,677	-10.2%	1,455	-14.3%	32,020	-10.2%
Exchange-Traded Funds	15	20	-24.0%	341	428	-20.4%	15	-24.0%	341	-20.4%
Structured Products Bonds	35 5	44 5	-21.0% -15.1%	760 101	919 114	-17.3% -11.0%	35 5	-21.0% -15.1%	760 101	-17.3% -11.0%
U.S. Cash Products (shares in millions) ⁵	1,814	2,372	-23.5%	36,276	47,442	-23.5%	1,814	-23.5%	36,276	-23.5%
NYSE Listed (Tape A) Issues ⁴	1,014	2,312	-23.370	30,210	71,772	-23.370	1,014	-23.370	30,210	-23.370
Handled Volume ⁵	1,291	1,740	-25.8%	25,825	34,796	-25.8%	1,291	-25.8%	25,825	-25.8%
Matched Volume ⁶	1,217	1,644	-25.9%	24,346	32,872	-25.9%	1,217	-25.9%	24,346	-25.9%
Total NYSE Listed Consolidated Volume	4,014	4,849	-17.2%	80,286	96,985	-17.2%	4,014	-17.2%	80,286	-17.2%
Share of Total Consolidated Volume	20.00/	25.00/	0.70/	00.00/	25.00/	0.70/	00.00/	0.70/	20.00/	0.70/
Handled Volume ⁵ Matched Volume ⁶	32.2% 30.3%	35.9% 33.9%	-3.7% -3.6%	32.2% 30.3%	35.9% 33.9%	-3.7% -3.6%	32.2% 30.3%	-3.7% -3.6%	32.2% 30.3%	-3.7% -3.6%
NYSE Arca & Amex (Tape B) Listed Issues	00.070	00.070	0.070	00.070	00.070	0.070	00.070	0.070	00.070	0.070
Handled Volume ⁵	272	332	-18.3%	5,433	6,648	-18.3%	272	-18.3%	5,433	-18.3%
Matched Volume ⁶	242	298	-18.7%	4,850	5,968	-18.7%	242	-18.7%	4,850	-18.7%
Total NYSE Arca & Amex Listed Consolidated Volume	1,114	1,288	-13.5%	22,272	25,753	-13.5%	1,114	-13.5%	22,272	-13.5%
Share of Total Consolidated Volume Handled Volume ⁵	24.4%	25.8%	-1.4%	24.4%	25.8%	-1.4%	24.4%	-1.4%	24.4%	-1.4%
Matched Volume ⁶	21.8%	23.2%	-1.4%	21.8%	23.2%	-1.4%	21.8%	-1.4%	21.8%	-1.4%
Nasdaq Listed (Tape C) Issues										
Handled Volume ⁵	251	300	-16.3%	5,018	5,997	-16.3%	251	-16.3%	5,018	-16.3%
Matched Volume ⁶ Total Nasdaq Listed Consolidated Volume	214 1,818	255 2,044	-16.1% -11.1%	4,279 36,355	5,098 40,882	-16.1% -11.1%	214 1,818	-16.1% -11.1%	4,279 36,355	-16.1% -11.1%
Share of Total Consolidated Volume	1,010	2,044	-11.170	30,333	40,002	-11.170	1,010	-11.170	30,333	-11.170
Handled Volume ⁵	13.8%	14.7%	-0.9%	13.8%	14.7%	-0.9%	13.8%	-0.9%	13.8%	-0.9%
Matched Volume ⁶	11.8%	12.5%	-0.7%	11.8%	12.5%	-0.7%	11.8%	-0.7%	11.8%	-0.7%
Exchange-Traded Funds ^{5,7}										
Handled Volume ⁵	256	300	-14.7%	5,116	5,996	-14.7%	256	-14.7%	5,116	-14.7%
Matched Volume ⁶ Total ETF Consolidated Volume	228 1,074	270 1,175	-15.6% -8.7%	4,556 21,470	5,396 23,507	-15.6% -8.7%	228 1,074	-15.6% -8.7%	4,556 21,470	-15.6% -8.7%
Share of Total Consolidated Volume		, -					•			
Handled Volume ⁵	23.8%	25.5%	-1.7%	23.8%	25.5%	-1.7%	23.8%	-1.7%	23.8%	-1.7%
Matched Volume ⁶	21.2%	23.0%	-1.8%	21.2%	23.0%	-1.8%	21.2%	-1.8%	21.2%	-1.8%

¹ Data includes currency products.

² Includes all trading activities for Bclear, NYSE Liffe's clearing service for wholesale derivatives.

³ Includes trading in U.S. equity options contracts, not equity-index options.

⁴ Includes all volume executed in NYSE Group crossing sessions.

⁵ Represents the total number of shares of equity securities and ETFs internally matched on the NYSE Group's exchanges or routed to and executed at an external market center. NYSE Arca routing includes odd-lots.

⁶ Represents the total number of shares of equity securities and ETFs executed on the NYSE Group's exchanges.

Data included in previously identified categories.

^{*} ADVs calculated with the appropriate number of NYSE Liffe U.S. trading days.

Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape as reported for equity securities.

All trading activity is single-counted, except European cash trading which is double counted to include both buys and sells.